Thoracic surgery volume among the world’s highest for a single center
2015–Annual thoracic surgery volume has ranked among the world’s highest for a single center for years, with an MDT system centered on lung and esophageal cancers.
Back to home
Grade III-A · Thoracic oncology specialty hospital
Shanghai Chest Hospital
Lung cancerEsophageal cancer
Established
1957
Beds
1,400+
Annual Volume
35,000+
Shanghai
China’s first chest specialty hospital; top-tier lung cancer volumes and a core site for domestic lung drug registration trials.
About the Hospital
Shanghai Chest Hospital is China’s earliest specialty hospital for thoracic diseases, with the highest annual thoracic surgical volume nationally and world-leading minimally invasive surgery for lung, esophageal and mediastinal tumors; uniportal VATS techniques originated here and spread globally.
Its medical oncology (Professor Lu Shun’s team) leads multiple global multicenter studies, ranking nationally in novel-drug research for lung cancer with rare targets.
Hospital Strengths
01Highest thoracic surgical volume in China
Over ten thousand thoracic operations annually, with complete uniportal-VATS and robotic platforms and extensive experience in complex central lung cancers.
02Frontier of lung-cancer drug research
Studies led by Professor Lu Shun are published in NEJM and Lancet Oncology; patients can enroll early in globally synchronized trials.
03Distinctive tracheal and mediastinal surgery
High-difficulty procedures such as tracheal reconstruction and giant mediastinal tumor resection are routine, serving as a national referral center.
Key Departments
Thoracic SurgeryMedical Oncology (Lung)Radiation OncologyRespiratory MedicineEsophageal Surgery
Coordinated Treatment Directions
- 01Uniportal VATS and robotic lung cancer surgery
- 02Minimally invasive esophageal surgery and comprehensive care
- 03High-difficulty mediastinal and tracheal surgery
- 04Clinical studies of novel agents for rare-target lung cancer
Officially Reported Treatment Milestones
Perioperative immunochemotherapy study for lung cancer (Neotorch)
2024The Neotorch study led by Prof. Lu Shun established a perioperative immunochemotherapy model for resectable lung cancer, published in JAMA.
Accreditations & Platforms
- NHC-affiliated specialty hospital
- Shanghai Clinical Center for Lung Cancer